NGNE NEUROGENE INC revenue, earnings and financials
For the quarter ended June 30, 2026, NEUROGENE INC reported revenue of n/a, net income of −$34.5M and diluted EPS of −$1.53; for the fiscal year ended December 2025 revenue was $0, down 100.0% on the year before.
NGNE annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $0, gross profit n/a, operating income −$103M, net income −$90.4M (margin n/a), EPS −$4.24
- Fiscal year ended Dec 2024: revenue $925K, gross profit n/a, operating income −$82.6M, net income −$75.1M (margin -8123.7%), EPS −$4.28
- Fiscal year ended Dec 2023: revenue $0, gross profit n/a, operating income −$55.6M, net income −$36.3M (margin n/a), EPS n/a
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$56.5M, net income −$55.2M (margin n/a), EPS −$1.04
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$60.7M, net income −$60.7M (margin n/a), EPS −$1.10
NGNE quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$34.5M, EPS −$1.53
- Quarter ended Mar 31, 2026: revenue n/a, net income −$30.9M, EPS −$1.39
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$24.7M, EPS −$1.12
- Quarter ended Sep 30, 2025: revenue $0, net income −$21.0M, EPS −$0.99
- Quarter ended Jun 30, 2025: revenue $0 (down 100.0% year over year), net income −$22.0M, EPS −$1.05
- Quarter ended Mar 31, 2025: revenue n/a, net income −$22.6M, EPS −$1.08
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$19.5M, EPS −$1.00
- Quarter ended Sep 30, 2024: revenue $0, net income −$20.2M, EPS −$1.19
- Quarter ended Jun 30, 2024: revenue $925K, net income −$18.5M, EPS −$1.09
- Quarter ended Mar 31, 2024: revenue n/a, net income −$16.9M, EPS −$1.00
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income $2.38M, EPS n/a
- Quarter ended Sep 30, 2023: revenue $0, net income −$14.6M, EPS −$32.67
- Quarter ended Jun 30, 2023: revenue $0, net income −$11.9M, EPS −$26.68
- Quarter ended Mar 31, 2023: revenue n/a, net income −$12.3M, EPS −$0.26
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$11.1M, EPS $0.70
- Quarter ended Sep 30, 2022: revenue n/a, net income −$13.1M, EPS −$1.18
- Quarter ended Jun 30, 2022: revenue n/a, net income −$15.7M, EPS −$0.28
- Quarter ended Mar 31, 2022: revenue n/a, net income −$15.4M, EPS −$0.28
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$15.2M, EPS −$0.28
- Quarter ended Sep 30, 2021: revenue n/a, net income −$15.4M, EPS −$0.28
NGNE cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$77.2M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$70.6M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$51.4M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$52.8M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$47.6M, share buybacks n/a
NGNE balance sheet
- Jun 30, 2026: cash $112M, total assets $244M, total liabilities $27.2M, shareholders' equity $217M
- Mar 31, 2026: cash $124M, total assets $263M, total liabilities $25.4M, shareholders' equity $238M
- Dec 31, 2025: cash $104M, total assets $289M, total liabilities $23.7M, shareholders' equity $265M
- Sep 30, 2025: cash $71.0M, total assets $288M, total liabilities $22.3M, shareholders' equity $266M
- Jun 30, 2025: cash $58.8M, total assets $297M, total liabilities $24.1M, shareholders' equity $273M
- Mar 31, 2025: cash $70.8M, total assets $315M, total liabilities $23.5M, shareholders' equity $292M
- Dec 31, 2024: cash $137M, total assets $336M, total liabilities $25.4M, shareholders' equity $310M
- Sep 30, 2024: cash $66.6M, total assets $164M, total liabilities $26.7M, shareholders' equity $137M
What is NGNE's revenue?
NEUROGENE INC reported $0 of revenue for the fiscal year ended December 2025.
Is NGNE profitable?
No. NEUROGENE INC lost $111M over the last four quarters.
What is NGNE's EPS?
Diluted earnings per share over the last four quarters were −$5.03; −$1.53 in the latest quarter.